tetano
Editor, Senior Moderator
Neurol Res
. 2023 Jan 22;1-7.
doi: 10.1080/01616412.2023.2167536. Online ahead of print.
Clinical course and outcome of Covid-19 in patients with myasthenia gravis
Gonulden Aktoz[SUP] 1 [/SUP], Cavit Boz[SUP] 2 [/SUP], Serap Zengin[SUP] 2 [/SUP], Aleyna Caglar Okumus[SUP] 2 [/SUP], Hilal Horozoglu[SUP] 2 [/SUP], Fatma Kara[SUP] 2 [/SUP], Ebru Oral[SUP] 2 [/SUP], Mehmet Ozmenoglu[SUP] 2 [/SUP]
Affiliations
Abstract
Objectives: To analyze the prognosis and outcomes of COVID-19 in patients with MG and to determine factors associated with COVID-19 severity in patients with MG.
Methods: Information concerning COVID-19 occurrence in patients with MG was collected in this single-center observational study. Univariate and multivariate analyses were used to identify factors associated with severe Covid-19.
Results: Two hundred seventy-five of the 386 records of MG were included in this study. Eighty-two (29.8%) patients had concurrent COVID-19 . The patients' mean age was 50.3 ± 1.6 years, and the mean duration of MG was 6.7 ± 5.4 years. MG was diagnosed after COVID-19 in five cases. Covid-19 was mild in 45 patients (54.9%), moderate in 23 (28.1%), and severe in 14 (17.07%), while mortality occurred in four of the severe cases (4.9%). Three of the exitus patients were receiving rituximab therapy. Pre-Covid MG Activity of Daily Living (MG-ADL) severity scores were significantly high in severe cases. A history of myasthenic crisis was also higher in severe cases. Similarly, univariate and multivariate analyses revealed an association between severe COVID-19 and myasthenic crisis history and high pre-Covid MG-ADL. The type of MG treatment had no independent effect on COVID-19 severity.
Conclusion: The vast majority of the MG patients made a good recovery from Covid-19. The risk of severe COVID-19 is high in patients with high MG-ADL severity scores and a history of myasthenic crisis.
Keywords: Covid-19; Myasthenia gravis; coronavirus.
. 2023 Jan 22;1-7.
doi: 10.1080/01616412.2023.2167536. Online ahead of print.
Clinical course and outcome of Covid-19 in patients with myasthenia gravis
Gonulden Aktoz[SUP] 1 [/SUP], Cavit Boz[SUP] 2 [/SUP], Serap Zengin[SUP] 2 [/SUP], Aleyna Caglar Okumus[SUP] 2 [/SUP], Hilal Horozoglu[SUP] 2 [/SUP], Fatma Kara[SUP] 2 [/SUP], Ebru Oral[SUP] 2 [/SUP], Mehmet Ozmenoglu[SUP] 2 [/SUP]
Affiliations
- PMID: 36681934
- DOI: 10.1080/01616412.2023.2167536
Abstract
Objectives: To analyze the prognosis and outcomes of COVID-19 in patients with MG and to determine factors associated with COVID-19 severity in patients with MG.
Methods: Information concerning COVID-19 occurrence in patients with MG was collected in this single-center observational study. Univariate and multivariate analyses were used to identify factors associated with severe Covid-19.
Results: Two hundred seventy-five of the 386 records of MG were included in this study. Eighty-two (29.8%) patients had concurrent COVID-19 . The patients' mean age was 50.3 ± 1.6 years, and the mean duration of MG was 6.7 ± 5.4 years. MG was diagnosed after COVID-19 in five cases. Covid-19 was mild in 45 patients (54.9%), moderate in 23 (28.1%), and severe in 14 (17.07%), while mortality occurred in four of the severe cases (4.9%). Three of the exitus patients were receiving rituximab therapy. Pre-Covid MG Activity of Daily Living (MG-ADL) severity scores were significantly high in severe cases. A history of myasthenic crisis was also higher in severe cases. Similarly, univariate and multivariate analyses revealed an association between severe COVID-19 and myasthenic crisis history and high pre-Covid MG-ADL. The type of MG treatment had no independent effect on COVID-19 severity.
Conclusion: The vast majority of the MG patients made a good recovery from Covid-19. The risk of severe COVID-19 is high in patients with high MG-ADL severity scores and a history of myasthenic crisis.
Keywords: Covid-19; Myasthenia gravis; coronavirus.